Acumen Pharmaceuticals Inc - Asset Resilience Ratio
Acumen Pharmaceuticals Inc (ABOS) has an Asset Resilience Ratio of 51.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Acumen Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Acumen Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ABOS book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Acumen Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Acumen Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.88 Million | 51.19% |
| Total Liquid Assets | $62.88 Million | 51.19% |
Asset Resilience Insights
- Very High Liquidity: Acumen Pharmaceuticals Inc maintains exceptional liquid asset reserves at 51.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Acumen Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Acumen Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Acumen Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Acumen Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.19% | $62.88 Million | $122.83 Million | -5.69pp |
| 2024-12-31 | 56.88% | $135.93 Million | $238.99 Million | -0.08pp |
| 2023-12-31 | 56.96% | $176.64 Million | $310.12 Million | +32.79pp |
| 2022-12-31 | 24.16% | $47.50 Million | $196.59 Million | -7.13pp |
| 2021-12-31 | 31.29% | $72.08 Million | $230.33 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $44.43 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more